Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.